Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

53 results about "Dopaminergic" patented technology

Dopaminergic means "related to dopamine" (literally, "working on dopamine"), dopamine being a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain. Dopaminergic brain structures facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT₂), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as dopaminergic. Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol O-methyl transferase (COMT) may be referred to as dopaminergic as well. Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have dopaminergic effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT₂.

Electrochemical detection method of dopamine

The invention discloses an electrochemical detection method of dopamine, and belongs to the technical field of analysis. According to the method, SnS2 quantum dots are loaded on Zn-MOF and modified on an electrode, then gold nanoparticles and a sulfydryl-containing dopamine aptamer single chain are sequentially fixed on the electrode, an Apt / AuNPs / SnS2QDs (at) Zn-MOF / GCE composite electrode (in an open state) is formed, an electrochemical signal of the composite electrode is greatly improved, and based on specific recognition between dopamine and an aptamer chain, the electrochemical performance of the composite electrode is improved. A large cavity of Zn-MOF is used for packaging SnS2 quantum dots with excellent electrochemical properties, electrochemical signal amplification is achieved, when a target object dopamine exists, dopamine can quench an ECL signal, an electric signal is obviously reduced (in a closed state), and therefore a linear relation between the change of the electrochemical signal and the concentration of dopamine is constructed, and the electrochemical property of the electrochemical signal is improved. Therefore, high-sensitivity and high-selectivity detection of dopamine is realized.
Owner:JIANGXI NORMAL UNIV

Composition and Method for Treating Metabolic Disorders

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Owner:VEROSCIENCE LLC

Cell containing dopamine fluorescence report system and asynchronous co-culture method

ActiveCN119776284ANervous disorderMicrobiological testing/measurementSomatic cellManagement of Parkinson's disease
The invention relates to a genetically modified induced neural stem cell and an asynchronous co-culture method. By providing a CRISPR / Cas9 engineered Nurr1-driven dopamine energy report induced neural stem cell model, the differentiation of dopaminergic neural precursor cells and neurons can be monitored in real time, a key pathway related to differentiation heterogeneity is revealed through RNA sequencing, an asynchronous co-culture method is established, and the method has the advantages of simple operation, low cost and high efficiency. The yield and purity of the dopaminergic nerve precursor cells can be improved, and the dopaminergic nerve precursor cells are successfully transplanted and differentiated into dopaminergic neurons in mouse striatum to prove the treatment potential of the dopaminergic nerve precursor cells for Parkinson's disease.
Owner:XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI

C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof

The present invention provides a C-terminal CDNF fragment sequence or a sequence which has at least 80% homology or sequence identity to said sequence. The C-terminal CDNF fragment protects ER stressed neurons, motoneurons and dopaminergic neurons and the fragment is capable of penetrating neuronal cell membrane as well as the blood-brain-barrier. The present invention further provides said fragment and pharmaceutical compositions comprising said fragment for use in treatments of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders. The present invention is also providing a C-terminal MANF fragment sequence or a sequence which has at least 80% homology or sequence identity to the said sequence and pharmaceutical compositions comprising said MANF fragment for use in the treatment of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders.
Owner:MYNEUROCURE OY

Preparation method of midbrain dopaminergic nerve precursor cells

The invention provides a method for preparing human midbrain dopaminergic nerve precursor cells. The method comprises the step of culturing human pluripotent stem cells in a culture medium with determined chemical components so as to finally obtain the human midbrain dopaminergic nerve precursor cells with expected functions. The invention also relates to functional human midbrain dopaminergic nerve precursor cells obtained by said method, as well as to compositions comprising such cells. The invention further provides application of the midbrain dopaminergic nerve precursor cell and a composition containing the midbrain dopaminergic nerve precursor cell in prevention, modeling and / or treatment of neurological disorders, and particularly, the preparation method of the human midbrain dopaminergic nerve precursor cell can be adapted to be used for preparing the human midbrain dopaminergic nerve precursor cell suitable for clinical application.
Owner:SHANGHAI HUOJIANDE BIOPHARMACEUTICAL CO LTD

Dopamine D2 receptor ligands

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.
Owner:THE BROAD INST INC +1

Digital therapeutics and combination therapy for the treatment of parkinsons disease

Provided is a method of digital therapeutics for modulating one or more Parkinson's disease-related markers, symptoms, or disease progression in an individual, on a standalone basis or by combining them with medicinal agents, particularly dopaminergic agents. Also provided are corresponding systems for implementing, delivering, and adapting such therapeutic interventions.
Owner:REMEPY HEALTH LTD

Composition and method for treating metabolic disorders

ActiveUS12668590B2PhysiologyPrediabetes
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Owner:VEROSCIENCE LLC

Low-dose dopaminergic drugs to delay the progression of spinocerebellar ataxia type 3 and alzheimer's disease

The present invention refers to dopaminergic drugs such as dopamine precursors and aromatic L-amino acid decarboxylase (AADC) inhibitors for use in a treatment to delay the progression of pathologies in which abnormal amyloid deposits spread to different brain regions, consisting of Spinocerebellar Ataxia Type 3 and Alzheimer's Disease, administered in levodopa-equivalent doses below 300 mg / day. The present invention further refers to pharmaceutical formulations comprising the said dopaminergic drugs. The present invention's compounds pharmaceutical formulations and uses may be advantageously employed in a treatment to prevent further accumulation of amyloid deposits in neurons, and minimize adverse effects associated with the prolonged use of dopamine precursors and / or their peripheral degradation.
Owner:I3S - INST OF HEALTH RES & INNOVATION ASSOC

Digital therapeutics and combination therapy for the treatment of parkinson's disease

Provided is a method of digital therapeutics for modulating one or more Parkinson's disease-related markers, symptoms, or disease progression in an individual, on a standalone basis or by combining them with medicinal agents, particularly dopaminergic agents. Also provided are corresponding systems for implementing, delivering, and adapting such therapeutic interventions.
Owner:REMEPY HEALTH LTD

Method for identifying dopaminergic neurons and progenitor cells

This provides a molecular diagnostic tool useful for the efficient and accurate characterization of the discriminative and functional properties of iPSC-derived dopaminergic neurons. [Solution] A computer-based method for identifying determined dopaminergic progenitor cells within an in vitro population of neural progenitor cells is provided, comprising: receiving a test dataset containing data such as gene expression profile information relating to an in vitro population of neural progenitor cells; querying a gene expression reference database and comparing the test dataset with the gene expression reference database, wherein the gene expression reference database contains gene expression profile information of the desired determined dopaminergic progenitor cells; and outputting a computer-calculated label classification that includes an indication of whether or not the in vitro population of neural progenitor cells contains the determined dopaminergic progenitor cells.
Owner:THE SCRIPPS RES INST +1

In-vitro preparation method for midbrain dopaminergic progenitor cell population

PCT designated stageWO2025252180A1Nervous disorderMicrobiological testing/measurementProgenitorMidbrain
Provided is a method for differentiating pluripotent stem cells in vitro to prepare a cell population mainly composed of midbrain floor plate dopaminergic progenitor cells, wherein the progenitor cells can efficiently and directionally differentiate into midbrain dopaminergic neuron precursors and midbrain dopaminergic neurons after being transplanted into a subject. Further provided is a cell population prepared by the method, a pharmaceutical composition containing the cell population, and a method for using the cell population or the pharmaceutical composition to treat or ameliorate a neurological disorder caused by a reduction in the number of midbrain dopaminergic neurons and / or impairment of function thereof.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI +1

Continuous delivery system comprising cannabinoid and medical use thereof

Compositions comprising 0.1 to 50% delta-9-tetrahydrocannabinol and / or cannabidiol, the forms of which are suitable for continuous delivery, and their use in the treatment of various diseases and pathological conditions are disclosed. In a preferred embodiment, the composition is in a form suitable for delivery by a portable infusion pump or transdermal patch. The conditions to be treated include pain, cancer, seizure conditions, and Parkinson's disease. The composition may optionally further comprise an additional active agent, such as a dopaminergic agent, depending on the condition to be treated.
Owner:パイク セラピューティクスインコーポレイテッド

An agent that increaes NATO3 expression and / or activity for use in the treatment of neurological disorders

The present invention relates to an agent that increases Nato3 expression and / or activity for use in preventing or treating a neurological disorder and related methods and uses. The present invention also relates to an expression construct or viral vector encoding an agent that increases Nato3 expression and / or activity and a host cell comprising said vector. The present invention also relates to a dopaminergic neuron or a dopaminergic progenitor comprising an expression construct encoding an agent that increases Nato3 expression and / or activity and a method of screening for a compound that improves dopaminergic function in a dopaminergic neuron.
Owner:UNIVERSITY OF GENEVA

A highly sensitive screening method for thyroid hormone disruptors

ActiveCN118883476BColor/spectral properties measurementsBiotechnologyThyroid hormones
The present application relates to a kind of thyroid hormone interferent high-sensitivity screening method, belong to new pollutant screening method technical field.The present application is based on the biological recognition performance of polypeptide and the peroxidase-like activity of nano gold combined with polypeptide material, based on this, a kind of thyroid hormone interferent screening method under medium alkaline condition can guarantee the activity of polypeptide and also can play the enzyme activity of nano gold.The dopamine can be catalyzed by nano gold under medium alkaline condition and quickly generate red product.Once interferent combines specific recognition polypeptide, occupies the enzyme activity recognition site of nano gold, reduces enzyme activity, in dopamine color system, different absorbance values are shown, so as to show the thyroid hormone interference toxic effect, reach the purpose of recognizing thyroid hormone interferent.The method does not need to use a large amount of organic solvent, and toxicity evaluation of thyroid hormone interferent can be realized by absorbance determination, with the advantages of simple preparation, low cost, high sensitivity.
Owner:HUAZHONG UNIV OF SCI & TECH

In vitro differentiation method of stem cells

PendingCN121592586ANervous disorderCulture processDopaminergicDegenerative Disorder
Provided are methods for in vitro induced differentiation of embryonic stem cells or pluripotent stem cells into dopaminergic neural progenitor cells, dopaminergic neural precursor cells and / or dopaminergic neurons. Also provided are media for use in the method, cell populations obtained using the method, and the use of the obtained cell populations in the prevention and / or treatment of diseases and / or dysfunctions associated with dopaminergic neuron degenerative disorders.
Owner:XELLSMART BIOMEDICAL (SUZHOU) CO LTD

Substituted furopyrimidine compounds as PDE1 inhibitors

Substituted furopyrimidine chemical entities of general formula (I): wherein R a has any of the values described herein, and compositions comprising such chemical entities; methods for preparing them; and their use in various methods, including metabolic and reaction kinetics studies; detection and imaging techniques; radiotherapy; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent loss of function; treating stroke, including cognitive and motor function deficits during stroke rehabilitation; promoting neuroprotection and neurorestoration; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular disorders, renal disorders, hematological disorders, gastrointestinal disorders, liver disorders, cancer, fertility disorders, and metabolic disorders.
Owner:DART NEUROSCIENCE LLC

Method for improving reverse electron transfer rate and energy metabolism level of shewanella single cell by preparing artificial conductive path

Shewanella bacteria are mode electrochemically active bacteria and have bidirectional electron transfer capability, but the reverse electron transfer rate is slower. In order to solve the problem, the invention discloses a method for synchronously constructing an artificial conductive path in shewanella bacteria attachment so as to improve the electron transfer rate of a bacteria-electrode interface and the energy metabolism activity of bacteria. By utilizing the method, after dopamine is subjected to in-situ electropolymerization in the adsorption process of shewanella tamariscina PV-4, polydopamine is formed in a bacterium-electrode interface area, and the current transferred by reverse electrons is improved by 3.46 times. Due to the fact that polydopamine can serve as an artificial conductive path, the reverse electron transfer capacity of shewanella single cells is improved, and the intracellular energy metabolism level is improved through faster electron transfer.
Owner:BEIJING INST OF TECH

Methods and compositions for selective generation of dopaminergic precursors

The present invention provides methods of transdifferentiating a somatic cell, e.g., a fibroblast, to an induced dopaminergic precursor cell (iDP) in vitro. The methods include ectopically expressing genes of (1) one or both of Brn2 and Brn4, or a variant thereof, (2) Sox2, or a variant thereof, and (3) one or both of Foxa2 and Lmx1a, or a variant thereof, in the somatic cell, and methods for treating a neurodegenerative disease, such as Parkinson's disease, with the iDP.
Owner:TONGJI UNIV +1

Therapeutic agent for non-motor symptoms associated with parkinson's disease

The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and / or an effect of preventing the recurrence of the same.
Owner:NEUROINNOVATECH APS

Method for producing nerve cells

PCT designated stageWO2026141672A1Induced pluripotent stem cellLPA Receptors
The present application provides a method for producing, from pluripotent stem cells, neural progenitor cells of the midbrain floor plate region or dopaminergic neural progenitor cells, the method comprising (1) inducing differentiation of pluripotent stem cells into neural progenitor cells of the midbrain floor plate region, and optionally (2) inducing differentiation of the neural progenitor cells of the midbrain floor plate region, which are obtained by the differentiation induced in (1), into dopaminergic neural progenitor cells, wherein all or part of the differentiation induced in (1) includes culturing the cells in a medium containing an agonist for LPA receptor.
Owner:RACTHERA CO LTD +1

Dopaminergic imaging to predict treatment response in mental illness

ActiveUS12608794B2Image enhancementImage analysisPrediction algorithmsAntipsychotic Medications
A neuroimaging-based approach to predict treatment response in mental disorders by acquiring and analysing brain PET dopamine measures from patients. The method uses a short, simplified protocol for [18F]FDOPA brain PET imaging adapted for clinical practice. Individual [18F]FDOPA brain PET data are then quantified with a fully-automated analysis pipeline to extract information on the dopamine function of the subject. This information coupled with clinical information is run through a prediction algorithm to identify those patients whose illness will not respond to conventional antipsychotics.
Owner:KINGS COLLEGE LONDON

Manganese-based high-performance composite positive electrode material coated with polydopamine and grown on MXene material in situ and preparation method of manganese-based high-performance composite positive electrode material

The invention discloses a manganese-based high-performance composite positive electrode material coated with polydopamine and grown on an MXene material in situ and a preparation method of the manganese-based high-performance composite positive electrode material. The preparation method comprises the following steps: (1) preparing Ni-gamma-MnO2 / MXene; and (2) preparation of the Ni-gamma-MnO2 / MXene (at) PDA. According to the technical scheme, nickel and manganese dioxide are promoted to realize in-situ growth on an MXene substrate by virtue of a hydrothermal synthesis method, so that a composite material with a specific structure is constructed, then, an active material containing the composite structure is uniformly dispersed in a tris buffer solution environment, and on the basis, oxygen is used as an initiator to trigger a self-polymerization reaction, so that the nickel-manganese dioxide composite material is obtained. According to the present invention, the surface of the active material can be tightly coated with the polydopamine in the highly uniform manner, the preparation process is simple, the raw material is cheap, and the coating of the polydopamine can reduce the effective contact degree between the aqueous electrolyte and MnO2, reduce the dissolution of MnOOH, and further make the structure more stable.
Owner:ZHEJIANG KAN BATTERY CO LTD

A manganese-based high-performance composite cathode material coated with polydopamine and grown in situ on a MXene material and a preparation method thereof

The application discloses a kind of polydopamine-coated manganese-based high-performance composite positive electrode materials and its preparation method, which is in-situ grown on MXene material, comprising the following steps: (1) preparation of Ni-gamma-MnO2 / MXene;(2) preparation of Ni-gamma-MnO2 / MXene@PDA.This technical solution promotes in-situ growth of nickel and manganese dioxide on MXene substrate by means of hydrothermal synthesis method, to construct a composite material with a specific structure, then, active material containing the above composite structure is uniformly dispersed in tris buffer solution environment, on this basis, oxygen is used as initiator to trigger the polymerization reaction, so that polydopamine can tightly wrap the surface of active material in a highly uniform manner, the preparation process is simple, raw materials are cheap, and the coating of polydopamine can reduce the effective contact degree between aqueous electrolyte and MnO2, reduce the dissolution of MnOOH, and make the structure more stable.
Owner:ZHEJIANG KAN BATTERY CO LTD

Kit for inducing differentiation of stem cells into dopaminergic neural precursor cells and / or dopamine neurons, and use thereof

Provided are a kit for inducing differentiation of stem cells into dopaminergic neural precursor cells and / or dopamine neurons, and a use thereof. The kit uses chemically defined culture media, chemical small molecules and cytokines, and does not involve substances such as animal-derived components which easily cause unstable factors such as batch-to-batch variation. Moreover, the differentiation period is shortened, and the kit can be used in clinical practice.
Owner:XELLSMART BIOMEDICAL (SUZHOU) CO LTD

Nerve cell with conditional immune escape function and suicide function, and establishment method and application thereof

The invention provides a nerve cell with a conditional immune escape function and a suicide function as well as an establishment method and application of the nerve cell. The invention discloses a space-time specific regulation element which can form a space-time specific promoter to regulate the expression of a target gene in a dopaminergic nerve precursor stage (mDAP). In addition, the invention also discloses a modified induced pluripotent stem cell and a nerve cell which is obtained by differentiation and has a conditional immune escape function and a suicide function. The cell can automatically trigger immune escape in the early stage of the dopamine energy precursor, and synchronously has a drug controllable self-destruction function.
Owner:SHANGHAI YUANVORE MEDICINE TECHNOLOGY CO LTD

Surface chemical modification substrate and preparation method thereof

PendingCN120607731ADihydroxyphenylalanineDopaminergic
The invention relates to a surface chemical modification substrate and a preparation method thereof. According to the preparation method, surface modification is realized by utilizing the characteristic that a catechol modifier such as dihydroxyphenylalanine or dopamine can be subjected to auto-polymerization deposition on the surface of a resin substrate. After modification, new polar groups such as hydroxyl, carboxyl and amino can be generated on the surface of the substrate, and the polar groups can increase the chemical bonding effect between the substrate and copper and improve the interface bonding force.
Owner:INST OF MICROELECTRONICS CHINESE ACAD OF SCI LTD

Culture medium, coating matrix and method for maturing midbrain dopaminergic progenitor cells

The present disclosure described herein provides, inter alia, an expansion method for expanding mDAPs and a culture medium and a coating matrix combination used in the expansion method, as well as a maturation method for maturing mDAPs and a culture medium used in the maturation method. The present disclosure also provides a substantially homogeneous population of mDAPs and a substantially homogeneous population of mDANs.
Owner:NUWACELL BIOTECHNOLOGIES CO LTD